ホーム500124 • BOM
ドクター・レッディーズ・ラボラトリーズ
₹1,179.85
1月28日, 16:01:35 GMT+5:30 · INR · BOM · 免責条項
株式IN 上場銘柄IN 所在
前日の終値
₹1,197.40
日次変動幅
₹1,165.00 - ₹1,197.40
年間変動幅
₹1,120.01 - ₹1,420.20
時価総額
9831.63億 INR
平均取引高
9.57万
株価収益率
18.32
配当利回り
0.68%
優先市場
NSE
CDP 気候変動スコア
A-
ニュース トピック
DRREDDY
1.15%
RDY
0.88%
DRREDDY
1.15%
RDY
0.88%
財務情報
損益計算書
収益
純利益
(INR)2024年12月前年比変化率
収益
835.86億15.85%
営業費用
303.44億19.95%
純利益
141.33億2.49%
純利益率
16.91-11.51%
1 株当たりの収益
16.941.81%
EBITDA
234.27億13.31%
実効税率
25.10%
総資産
負債総額
(INR)2024年12月前年比変化率
現金および短期投資
599.22億-17.41%
総資産
4810.59億29.02%
負債総額
1594.94億51.91%
純資産
3215.65億
発行済み株式
8.33億
帳簿価格
3.14
総資産利益率
9.88%
資本利益率
12.81%
現金の純増減額
(INR)2024年12月前年比変化率
純利益
141.33億2.49%
営業キャッシュ フロー
66.20億39.75%
投資キャッシュ フロー
-54.58億66.27%
財務キャッシュ フロー
5.90億-88.83%
現金の純増減額
17.47億129.12%
フリー キャッシュ フロー
-3.83億90.46%
概要
Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology. Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to other less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe. By 2007, Dr. Wikipedia
設立
1984
ウェブサイト
従業員数
27,048
検索
検索をクリア
検索を終了
Google アプリ
メインメニュー